IL-1 trap Regeneron/Novartis

Current Opinion in Investigational Drugs

Volumn 4, Issue 5, 2003, Pages 593-597

  Gabay, Cem ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; COLLAGEN TYPE 2; CYTOKINE; ETANERCEPT; GROWTH FACTOR; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR TYPE 1; INTERLEUKIN 1 RECEPTOR TYPE 2; INTERLEUKIN 1 SIGNALING INHIBITOR; INTERLEUKIN 1 TRAP; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; METHOTREXATE; PRALNACASAN; PROTEOGLYCAN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BINDING AFFINITY; CANCER RISK; CLINICAL TRIAL; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INJECTION PAIN; MONOTHERAPY; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TUBERCULOSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; HUMANS; INTERLEUKIN-1; TECHNOLOGY, PHARMACEUTICAL;

EID: 0038179364     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. 202083 Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arend WP, Dayer JM Arthritis Rheum 1995 38 2 151-160 A comprehensive review on the rationale behind targeting IL-1 and TNFα in the treatment of RA.
2. 266429 Biologic basis for interleukin-1 in disease. Dinarello CA Blood 1996 87 6 2095-2147 An exhaustive review covering 586 citations on structure, function and importance of IL-1 and IL-1 receptors in health and various diseases.
3. 394203 Regeneron initiates rheumatoid arthritis trial: IL-1 trap is first of Regeneron's family of cytokine inhibitors to enter clinical trials. Regeneron Pharmaceuticals Inc Press Release 2000 December 18
4. 407756 Regeneron announces first quarter 2001 results. Regeneron Pharmaceuticals Inc Press Release 2001 May 01
5. 429356 Regeneron announces encouraging initial results in phase I study of IL-1 trap in patients with rheumatoid arthritis. Regeneron Pharmaceuticals Inc Press Release 2001 November 14 Results from pharmacokinetic studies of IL-1 trap following subcutaneous injections in patients with RA.
6. 435060 Regeneron's IL1 trap demonstrates clinical activity in patients with rheumatoid arthritis. Regeneron Pharmaceuticals Inc Press Release 2002 January 07 The serum levels of C-reactive protein decreased in a dose-dependent manner in RA patients treated with IL-1 trap.
7. 450049 Advances in Anti-Arthritic Agents - SMi's Third Annual Conference (Part I), London, UK. Norman P IDDB Meeting Report 2002 April 23-24 Several anti-arthritic agents are discussed in this report including IL-1 trap, of which the first dose-escalating, double-blind, placebo-controlled trial in RA patients is reported. A significantly higher percentage of patients achieved the ACR20 criteria of improvement in the IL-1 trap group than in the placebo group.
8. 454821 Cytokine inhibitors in the treatment of rheumatoid arthritis. Gabay C Expert Opin Biol Ther 2002 2 2 135-149 A comprehensive review article on cytokine inhibitors, in which the results of trials with IL-1Ra are described in detail. In addition, other potenial strategies aimed at inhibiting IL-1 are discussed.
9. 457329 Regeneron granted license by Amgen and Immunex to interleukin-1 inhibitor patents. Regeneron Pharmaceuticals Inc Press Release 2002 July 08
10. 459031 Regeneron initiates phase II clinical trial of IL1 trap in patients with rheumatoid arthritis. Regeneron Pharmaceuticals Inc Press Release 2002 July 24
11. 468335 Phase IIa clinical trial results for pralnacasan in rheumatoid arthritis presented at ACR. Vertex Pharmaceuticals Inc Press Release 2002 October 29
12. 472434 A phase 1, single dose escalation study of IL-1 trap in patients with rheumatoid arthritis. Guler HP, Caldwell J, Littlejohn TIII, McIlwain H, Offenberg H, Stahl N Arthritis Rheum 2001 44 9 S370
13. 476363 Regeneron Pharmaceuticals Inc - Presentation at the JP Morgan H&Q 21st Annual Healthcare Conference. Regeneron Pharmaceuticals Inc Company Presentation 2003 January 7 1-32
14. 478437 Cytokine traps: Multi-component, high-affinity blockers of cytokine action. Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-Stec EM, Hartnett C, Pyles EA, Xu X, Daly TJ, Young MR, Fandl JP et al Nat Med 2003 9 1 47-52 This original article describes the in vitro and in vivo results with IL-1 trap and IL-4 trap.
15. 478748 Nails in the coffin: Increasing evidence for the role of rheumatic disease in the cardiovascular mortality of rheumatoid arthritis. Bacon PA, Townend JN Arthritis Rheum 2001 44 12 2707-2710
16. 478752 Setting the cytokine trap for autoimmunity. Dinarello CA Nat Med 2003 9 1 20-22
17. 478755 Anticytokine therapy for osteoarthritis. Goldring MB Expert Opin Biol Ther 2001 1 5 817-829
18. 478763 Safety of combination therapy with anakinra and etanercept in patients with rheumatoid arthritis. Schiff MH, Bulpitt K, Weaver AA Arthritis Rheum 2001 44 S83 This open-label clinical trial included 58 patients with active RA to whom IL-1Ra was administered in combination with etanercept. Eleven patients had serious side effects, including four patients with severe infection.
19. 483920 Regeneron and Novartis form strategic collaboration to develop and commercialize the IL-1 trap in rheumatoid arthritis and other indications. Regeneron Pharmaceuticals Inc Press Release 2003 March 28
20. 489301 Regeneron: Company update. Harr S, Husseini N, Wheeler J Morgan Stanley Dean Witter 2003 April 14 1-8
21. 489303 Research brief: Regeneron Pharmaceuticals Inc. King M, Solomon M, Cutler AD, Butz G Banc of America 2003 April 14 1-8